Description
Global Veterinary Medicine Market Research Report—Forecast till 2027
Market Synopsis
Global Veterinary Medicine Market is anticipated to witness a healthy CAGR of 5.57% during the review period of 2020 to 2027. The rising rates of pet ownership, increasing chronic diseases, and growing consumption of meat are expected to create many growth opportunities for the global market. Apart from meat utilization, the dairy items request has likewise flooded. Expanding meat and dairy utilization request the security of domesticated animals and consistent checking of their wellbeing to capture the spread of illnesses from creatures to people. Amid the developing meat utilization, the emphasis on improving the wellbeing of new meat has expanded.
The global veterinary medicine market is expected to register a significant market owing to the largest value at USD 28,012.73 Million in 2019. The increasing predominance of diseases in animals poses a serious threat to food security. Climate change and globalization are the major reasons attributing to the rise in diseases among animals. Moreover, the increase in the number of pet ownerships is propelling the requirement for better care of companion animals, driving the overall expenditure on pets.
Market Segmentation
Global Veterinary Medicine Market has been classified into Animal Type, Product, Route of Administration, and Distribution Channel.
In terms of animal type, the global market has been divided into domesticated and companion.
In terms of product segments, the market is segmented into drugs and vaccines. By the route of administration, the market is categorized into oral, parental, and others. Based on the distribution channel, the market is divided into veterinary hospitals & clinics, retail stores, and online pharmacies.
Regional Analysis
Geographically, the Global Veterinary Medicine Market has been divided into the Americas, Europe, Asia-Pacific, and Middle East & Africa.
The Americas is likely to contribute the largest market owing to the increase in companion animal ownership and the rising prevalence of animal diseases in the region. As per Atlas Dental, a total of 69,075 dental operations were performed in German hospitals in 2017. Additionally, the global market growth is attributed to the increasing population of pets and livestock with a high number of veterinary practices.
Europe contributes to the second-largest market in the global veterinary medicine market during the review period. The regional market is driven by the increasing prevalence of diseases, new product approvals, and the existence of developed veterinary healthcare infrastructure.
Asia-Pacific is expected to attain the fastest-growing market during the review period. The regional market is driven by the increasing penetration of the veterinary sector, the increase in the number of private veterinary clinics, growing awareness about animal welfare, and government campaigns for the welfare of pet animals in China, Japan, India, South Korea, and Australia.
The veterinary medicine market in Middle East & Africa is anticipated to register steady growth during the forecast period owing to the presence of developing countries in the region.
Major Players
The Key Players in the Global Veterinary Medicine Market are Boehringer Ingelheim, Ceva, Chanelle Pharma Group, Dechra Pharmaceuticals plc, Elanco, Merck Animal Health, Norbrook Laboratories, Vetoquinol S.A., Bayer AG, and Zoetis.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
Table of Contents
TABLE OF CONTENT
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY 15
2.2 RESEARCH OBJECTIVE 15
2.3 MARKET STRUCTURE 15
2.4 ASSUMPTIONS & LIMITATIONS 16
3 RESEARCH METHODOLOGY
3.1 DATA MINING 17
3.2 SECONDARY RESEARCH 18
3.3 PRIMARY RESEARCH 19
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 20
3.5 FORECASTING TECHNIQUES 20
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 22
3.6.1 BOTTOM-UP APPROACH 23
3.6.2 TOP-DOWN APPROACH 23
3.7 DATA TRIANGULATION 24
3.8 VALIDATION 24
4 MARKET DYNAMICS
4.1 OVERVIEW 25
4.2 DRIVERS 26
4.2.1 GROWING RATES OF PET OWNERSHIP 26
4.2.2 RISING ZOONOTIC & CHRONIC DISEASES ANIMALS 26
4.2.3 INCREASING MEAT CONSUMPTION ATTRACTING MANDATORY VACCINATION 26
4.3 RESTRAINT 27
4.3.1 SHORTAGE OF VETERINARIANS 27
4.3.2 STRINGENT REGULATORY GUIDELINES PERTAINING TO VACCINES APPROVAL FOR ANIMALS 27
4.4 OPPORTUNITY 28
4.4.1 INCREASING INVESTMENT IN VETERINARY HOSPITALS 28
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS 29
5.1.1 R&D 30
5.1.2 MANUFACTURING 30
5.1.3 DISTRIBUTION & SALES 30
5.1.4 POST-SALES REVIEW/MONITORING 30
5.2 PORTER’S FIVE FORCES MODEL 31
5.2.1 THREAT OF NEW ENTRANTS 31
5.2.2 BARGAINING POWER OF SUPPLIERS 32
5.2.3 THREAT OF SUBSTITUTES 32
5.2.4 BARGAINING POWER OF BUYERS 32
5.2.5 INTENSITY OF RIVALRY 32
5.3 IMPACT OF COVID-19 32
5.3.1 OVERVIEW 32
5.3.2 IMPACT ON MEAT CONSUMPTION 33
5.3.3 IMPACT ON VETERINARY MEDICINE MARKET 33
6 GLOBAL VETERINARY MEDICINE MARKET, BY ANIMAL TYPE
6.1 OVERVIEW 34
6.2 DOMESTICATED 35
6.3 COMPANION 35
7 GLOBAL VETERINARY MEDICINE MARKET, BY PRODUCT
7.1 OVERVIEW 37
7.2 DRUG 38
7.3 VACCINES 39
8 GLOBAL VETERINARY MEDICINE MARKET, BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW 40
8.2 ORAL 41
8.3 PARENTERAL 41
8.4 OTHERS 42
9 GLOBAL VETERINARY MEDICINE MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW 43
9.2 VETERINARY HOSPITALS & CLINICS 44
9.3 RETAIL STORES 44
9.4 ONLINE PHARMACIES 45
10 GLOBAL VETERINARY MEDICINE MARKET, BY REGION
10.1 OVERVIEW 46
10.2 AMERICAS 48
10.2.1 NORTH AMERICA 50
10.2.1.1 US 52
10.2.1.2 CANADA 53
10.2.2 LATIN AMERICA 54
10.3 EUROPE 56
10.3.1 WESTERN EUROPE 58
10.3.1.1 GERMANY 60
10.3.1.2 UK 61
10.3.1.3 FRANCE 62
10.3.1.4 ITALY 63
10.3.1.5 SPAIN 64
10.3.1.6 REST OF WESTERN EUROPE 65
10.3.2 EASTERN EUROPE 67
10.4 ASIA-PACIFIC 69
10.4.1 CHINA 71
10.4.2 JAPAN 72
10.4.3 INDIA 73
10.4.4 AUSTRALIA 74
10.4.5 SOUTH KOREA 75
10.4.6 REST OF ASIA-PACIFIC 76
10.5 MIDDLE EAST & AFRICA 78
10.5.1 SAUDI ARABIA 80
10.5.2 UNITED ARAB EMIRATES 81
10.5.3 OMAN 83
10.5.4 KUWAIT 84
10.5.5 QATAR 85
10.5.6 REST OF THE MIDDLE EAST & AFRICA 86
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW 88
11.2 COMPETITIVE BENCHMARKING 89
11.3 GLOBAL VETERINARY MEDICINE MARKET: COMPANY RANKING 90
11.4 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 91
11.5 MAJOR GROWTH STRATEGY IN THE GLOBAL VETERINARY MEDICINE MARKET 91
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 92
11.6.1 NEW PRODUCT LAUNCHES 92
11.6.2 PARTNERSHIPS/AGREEMENTS 92
11.6.3 EXPANSIONS 93
11.6.4 ACQUISITIONS 93
11.7 FINANCIAL MATRIX 94
12 COMPANY PROFILES
12.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 96
12.1.1 COMPANY OVERVIEW 96
12.1.2 FINANCIAL OVERVIEW 97
12.1.3 PRODUCTS/SERVICES OFFERED 97
12.1.4 KEY DEVELOPMENTS 99
12.1.5 SWOT ANALYSIS 99
12.1.6 KEY STRATEGIES 100
12.2 CEVA 101
12.2.1 COMPANY OVERVIEW 101
12.2.2 FINANCIAL OVERVIEW 101
12.2.3 PRODUCTS/SERVICES OFFERED 102
12.2.4 KEY DEVELOPMENTS 102
12.2.5 SWOT ANALYSIS 103
12.2.6 KEY STRATEGIES 103
12.3 ZOETIS 104
12.3.1 COMPANY OVERVIEW 104
12.3.2 FINANCIAL OVERVIEW 104
12.3.3 PRODUCTS/SERVICES OFFERED 105
12.3.4 KEY DEVELOPMENTS 107
12.3.5 SWOT ANALYSIS 107
12.3.6 KEY STRATEGIES 107
12.4 MERCK ANIMAL HEALTH 108
12.4.1 COMPANY OVERVIEW 108
12.4.2 FINANCIAL OVERVIEW 109
12.4.3 PRODUCTS/SERVICES OFFERED 110
12.4.4 KEY DEVELOPMENTS 111
12.4.5 SWOT ANALYSIS 112
12.4.6 KEY STRATEGIES 112
12.5 CHANELLE PHARMA GROUP 113
12.5.1 COMPANY OVERVIEW 113
12.5.2 FINANCIAL OVERVIEW 113
12.5.3 PRODUCTS/SERVICES OFFERED 113
12.5.4 KEY DEVELOPMENTS 115
12.5.5 SWOT ANALYSIS 115
12.5.6 KEY STRATEGIES 115
12.6 ELANCO 116
12.6.1 COMPANY OVERVIEW 116
12.6.2 FINANCIAL OVERVIEW 117
12.6.3 PRODUCTS/SERVICES OFFERED 118
12.6.4 KEY DEVELOPMENTS 119
12.6.5 SWOT ANALYSIS 120
12.6.6 KEY STRATEGIES 120
12.7 DECHRA PHARMACEUTICALS PLC 121
12.7.1 COMPANY OVERVIEW 121
12.7.2 FINANCIAL OVERVIEW 121
12.7.3 PRODUCTS/SERVICES OFFERED 122
12.7.4 KEY DEVELOPMENTS 123
12.7.5 SWOT ANALYSIS 123
12.7.6 KEY STRATEGIES 123
12.8 BAYER AG 124
12.8.1 COMPANY OVERVIEW 124
12.8.2 FINANCIAL OVERVIEW 124
12.8.3 PRODUCTS/SERVICES OFFERED 125
12.8.4 KEY DEVELOPMENTS 126
12.8.5 SWOT ANALYSIS 127
12.8.6 KEY STRATEGIES 127
12.9 VETOQUINOL SA. 128
12.9.1 COMPANY OVERVIEW 128
12.9.2 FINANCIAL OVERVIEW 128
12.9.3 PRODUCTS/SERVICES OFFERED 129
12.9.4 KEY DEVELOPMENTS 131
12.9.5 SWOT ANALYSIS 132
12.9.6 KEY STRATEGIES 132
12.10 NORBROOK LABORATORIES 133
12.10.1 COMPANY OVERVIEW 133
12.10.2 FINANCIAL OVERVIEW 133
12.10.3 PRODUCTS/SERVICES OFFERED 133
12.10.4 KEY DEVELOPMENTS 135
12.10.5 SWOT ANALYSIS 135
12.10.6 KEY STRATEGIES 136
13 APPENDIX
13.1 REFERENCES 137
13.2 RELATED REPORTS 138
